Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05599568
Other study ID # P-2022-168
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 15, 2022
Est. completion date May 30, 2025

Study information

Verified date April 2024
Source Rigshospitalet, Denmark
Contact Mads Stemmerik, MD
Phone +4535456126
Email mads.peter.godtfeldt.stemmerik@regionh.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The repeated bout effect (RBE) refers to the adaptation whereby a single bout of eccentric exercise protects against muscle damage from subsequent eccentric bouts. This effect has been shown in many muscle groups using both serum biomarkers, muscle soreness and imaging techniques. Though the effect is well described in healthy, it has never been studied in patients with neuromuscular diseases (NMDs). In healthy, the RBE is only described using eccentric exercise, but unlike healthy persons, patients with NMDs can experience significant muscle damage with concentric exercise. This raises the question, if patients with NMDs could also show RBE when performing concentric exercise.


Description:

The repeated bout effect (RBE) refers to the adaptation whereby a single bout of eccentric exercise protects against muscle damage from subsequent eccentric bouts. This effect has been shown in many muscle groups using both serum biomarkers, muscle soreness and imaging techniques. Though the effect is well described in healthy, it has never been studied in patients with neuromuscular diseases (NMDs). NMDs are a common term for diseases that affect the muscles by disease processes in the motor neuron, peripheral nerve, neuromuscular junction or the muscles. The diseases can cause symptoms such as muscle weakness, muscle fatigue and sometimes muscle pain and varying degrees of physical disability. As the mechanisms for disease varies among NMDs, it is likely that some patients will experience RBE in a similar fashion to healthy, while others may not. Recent years have shown significant breakthrough in the treatment development for various NMDs, and many of these treatments are currently or will soon be evaluated in clinical trials. As many trials will use exercise to evaluate treatment effect, it is vital to understand whether a single bout of exercise in itself provides a protective effect on the muscles of patients with NMDs. In healthy, the RBE is only described using eccentric exercise, but unlike healthy persons, patients with NMDs can experience significant muscle damage with concentric exercise. This raises the question, if patients with NMDs could also show RBE when performing concentric exercise.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date May 30, 2025
Est. primary completion date January 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age > 18 years - The ability to complete the exercise challenge - No concurrent medical condition that could interfere with interpretation of the results - Molecular diagnosis of the specific condition in specified patient groups or healthy control - No active muscle injury on the test day (caused by recent exercise, seizures, trauma, etc.) Exclusion Criteria: - Cardiac or pulmonary disease contraindicating peak exercise testing or strenuous exercise defined as NYHA-class III-IV - Veins that are too difficult to puncture for blood sampling, evaluated by the investigator - Severe muscle weakness, that prevents the subject completing the exercise test, evaluated by the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Exercise
Either concentric or excentric exercise

Locations

Country Name City State
Denmark Neuromuscular Research Unit, 3342 Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Mads Peter Godtfeldt Stemmerik

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Delta CK Change in peak kreatine kinase following first and second exercise bout. 1 month
See also
  Status Clinical Trial Phase
Recruiting NCT06374719 - WiTNNess - TNNT1 Myopathy Natural History Study
Not yet recruiting NCT03633565 - Comparative Study of Strategies for Management of Duchenne Myopathy (DM) Phase 4
Enrolling by invitation NCT02235220 - Reduction of Masticatory Muscle Activity by Restoring Canine Guidance N/A
Terminated NCT00278564 - Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases Phase 1
Completed NCT01642056 - EPI-743 for Metabolism or Mitochondrial Disorders Phase 1/Phase 2
Completed NCT02011282 - Electro-Neuro-Muscular Stimulation in ICU N/A
Completed NCT01702987 - Evaluation of Ubiquinol on Mitochondrial Oxidative Capacity in Statin Patients Using 31PMRS N/A
Active, not recruiting NCT01225614 - Efficacy and Tolerance of Early Launching of Nocturnal Non Invasive Phase 3
Recruiting NCT03749538 - Acute Transcranial Direct Current Stimulation in Patients With Systemic Autoimmune Myopathies N/A
Completed NCT02442986 - Neurological Outcome in Surgical and Non-surgical Septic Patients N/A
Recruiting NCT01022450 - Study of the Causes of the Breakdown of Muscle Fibers in Hospitalized Patients N/A
Withdrawn NCT00990834 - Muscle Characteristics Associated With Statin Therapy N/A
Active, not recruiting NCT00937001 - Critical Illness Myopathy as a Cause of Debilitating ICU-Acquired Weakness N/A
Recruiting NCT01353430 - Characterization of Inclusion Body Myopathy Associated With Paget's Disease of Bone and Frontotemporal Dementia (IBMPFD)
Completed NCT03751644 - Peripherical Neuromuscular Electrical Stimulation in Systemic Autoimmune Myopathies N/A
Completed NCT02765828 - Identification of Tongue Involvement in Late-Onset Pompe Disease
Withdrawn NCT02124070 - Therapeutic Effect of Recombinant Human Growth Hormone (rhGH) on the Myopathy of Cystinosis Phase 1/Phase 2
Completed NCT02706314 - Impact of Human Blood Serum From Critically Ill Patients on Human Colon Neuronal Networks.
Recruiting NCT03042286 - SAPhIRE Statin Adverse Drug Reaction
Not yet recruiting NCT04941079 - Safety and Efficacy of Inactivated SARS-CoV-2 Vaccine in Immune-related Myopathy (Myasthenia Gravis and Inflammatory Myopathy) Patients :a Prospective Observational Study